Amgen reveals midphase eczema data behind its $400M bet

When Amgen splashed $400 million upfront on Kyowa Kirin’s anti-OX40 antibody, the world was yet to see midphase data on the prospect. Amgen and Kyowa lifted the lid on the data over the weekend in a presentation of phase 2 results in eczema patients.